INDICATION AUCATZYL ® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...
HEXPOL has successfully approved materials from the Dryflex Circular TPE range to the Porsche PN 780 standard. The standard ...
Cell free RNA diagnostics market is projected to reach US$ 204.5 Mn by 2035, expanding at a CAGR of 14.5% from 2025 to 2035 ...
A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...
Operational real-world data analyzed from patients prescribed ZYNTEGLO™ and LYFGENIA™Data demonstrates the value proposition of one-time, durable gene therapy for the treatment of sickle cell disease ...
Building on its July 2025 announcement of a renewed shareholding structure and fresh investment in business development, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback